Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation

- NASDAQ Companies
  0

Phase 2 study results demonstrated the potential clinical benefit of exebacase, when used in addition to existing antibiotics, for the treatment of life-threatening MRSA bacteremiaExebacase Phase 2 study results supported FDA Breakthrough Therapy designation and the design of the ongoing Phase 3 DISRUPT study
Bay Street News

Contact Us

We're not around right now. But you can send us an email and we'll get back to you, asap.

Not readable? Change text. captcha txt

Start typing and press Enter to search